FDA approves Roche Rituxan for treatment of adult patients with moderate to severe normal herpes

herpes is a group of autoimmune diseases caused by autoantibodies produced by B cells in the immune system that attack the proteins that connect between skin epidermal cellsrecently, the U.SFDAapproved roche Rituxan (generic name: rituximab, rituxima) for the treatment of moderate to severe common herpes (PV) adult patientsit's worth noting that this is also the first biotherapy approved by the FDA to treat PVRituxan
Rituxan is a therapeutic monoclonal antibody that targets CD20 antigens that bind to normal and malignant B cell surfaces and then mobilizes the body's natural defenses to attack and kill labeled B cells, the FDA has granted Rituxan priority review qualification for the treatment of PV, breakthroughdrug(qualification, orphan drug qualification), so far, in addition to common herpes, Rituxan has also been approved for treatment of diseases including rheumatoid arthritis, granuloma polyvasitis, under the microscope polyvasitis and other diseasesthe studyapproved, based on data from the clinical study Ritux 3, which recruited 90 PV patients who were randomly divided into two programme groups: the CS standard dose protocol group and the Rituxan combined dose-reduced short-term low-dose oral CS program groupfinal results showed that Rituxan significantly increased the rate of PV remission while successfully reducing and/or discontinuing CS therapyspecific data were: 90% of patients in the Rituxan-CS scheme group reached the end point, compared with 28% in the CS scheme groupin addition,, Roche is conducting another Phase III study of PEMPHIX (NCT02383589) to assess the efficacy and safety of the CS protocol for the gradual reduction of the combined dose of Rituxan in relation to immunosuppressivepharmaceutical (McCocept)